A Phase 3 Dose Response Study to Assess the Safety and Efficacy of Nabiximols Oromucosal Spray (Sativex) in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis.

Trial Profile

A Phase 3 Dose Response Study to Assess the Safety and Efficacy of Nabiximols Oromucosal Spray (Sativex) in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Multiple sclerosis; Muscle spasticity
  • Focus Therapeutic Use
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 22 Aug 2016 New trial record
    • 10 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top